Five things to know:
1. Most of the affected patients developed symptoms such as pain, swelling or chills within several days of receiving the stem cell products. Liveyon recalled the products Sept. 28, 2018.
2. When the FDA inspected Genetech, which processed the stem cell products, it found problems with the manufacturing process.
3. The FDA found the Genetech facility did not determine if donors of the umbilical cord blood used to in these products were eligible by appropriately screening them for diseases, including HIV, hepatitis B and hepatitis C.
4. At present, the CDC is not aware of any HIV, hepatitis B or hepatitis C infections linked to the ReGen Series products.
5. Transmission risk is very low, but the CDC recommends affected patients talk to their healthcare provider about getting tested for HIV, hepatitis B and hepatitis C as a precaution.
More articles on biologics:
Global spine biologics market to hit $2.7B by 2024 — 18 key players
U of Missouri to release biojoint records amid allegations of false marketing: 5 things to know
Japan approves stem cell treatment for SCI — Some researchers doubt efficacy
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
